Project Grant HT94252410718
Award Date 9/1/24
Completion Date 8/31/27
Dollars Obligated $817K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Sarasota, FL 34243, USA
Similar Awards
- The Defense Health Agency awarded The Roskamp Institute, Inc. a $817,085 Project Grant under the Military Medical Research and Development program to conduct research on amnion cell secretome-mediated therapy for traumatic brain injury. The three-year award runs from June 1, 2023 to May 31, 2026 and will support The Roskamp Institute's investigation into potential therapies using amnion-derived cell treatments to address neuroinflammation and other vascular contributions to traumatic brain...
- The Defense Health Agency awarded a $749,905 Project Grant to The Roskamp Institute Inc. under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 2023 through September 2026 to investigate microglial NOX2/NLRP3 inflammasome activation and its role in driving tau pathology and cognitive impairments in chronic traumatic brain injury. Specifically, the Roskamp Institute will conduct basic, applied, and advanced biomedical...
- The Defense Health Agency awarded a $1,633,104 Project Grant to The Roskamp Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420) to develop highly selective DYRK1A inhibitors as a novel therapeutic approach for traumatic brain injury. The grant, which runs from June 15, 2024 to June 14, 2028, supports the organization's research to understand the causes of and find cures for neuropsychiatric and neurodegenerative disorders. The Roskamp Institute, a non-profit...
- The Defense Health Agency awarded a $489,997 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc. in Sarasota, Florida. The grant, awarded on September 1, 2024, will fund research to delineate the therapeutic effect of PTEN inhibition on mitigating chronic microglia activation and the chronic sequelae of repetitive mild traumatic brain injury (mTBI). The Roskamp Institute, a non-profit biotechnology research organization, has...
- This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $3,268,799.00 to The Roskamp Institute, Inc. to conduct research on the therapeutic effects of a novel blood-brain barrier-penetrating PPAR agonist for improving chronic outcomes following age-related repetitive mild traumatic brain injury. The award period runs from Sep 15, 2025 to Sep 14, 2029. The Roskamp Institute, a non-profit biotechnology research...
- This federal Project Grant award for $327,194 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc., a biotechnology research organization based in Sarasota, Florida. The purpose of this 3-year award, with a performance period from September 1, 2024 to August 31, 2027, is to conduct research on delineating the therapeutic effect of PTEN inhibition for mitigating chronic microglia activation and the...
- The U.S. Defense Health Agency awarded a $817,027 Project Grant to The Roskamp Institute, Inc. in Sarasota, Florida under the Military Medical Research and Development program (CFDA 12.420). The 3-year grant, running from August 15, 2023 to August 14, 2026, will support the institute's research on an "amnion-derived multipotent cell secretome-medicated therapy for Gulf War Illness." The Roskamp Institute is a non-profit biotechnology research organization that has previously...
- This $6,214,900 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports research on the role of genetic risk factors and immune response on neurovascular unit (NVU) function in post-traumatic brain injury (TBI) cognitive impairment. The primary awardee, the Scintillon Institute, a non-profit biomedical research organization in San Diego, California, will conduct this advanced scientific investigation over...
- The Defense Health Agency awarded a $1,973,398 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Azevan Pharmaceuticals Inc. in Bethlehem, PA. The grant supports the development of a new drug to prevent the effects of mild traumatic brain injury (TBI) or concussion. The research project will be conducted over a 2-year period from June 2024 to June 2026. The goal is to advance the development of an innovative medical solution to address this critical...
- The U.S. Defense Health Agency awarded a $2,550,000 Project Grant to Alcamena Stem Cell Therapeutics, LLC, a small disadvantaged business in Spencerville, MD, to develop a new drug modality to restore cognitive and psychological health after traumatic brain injury. This award is part of the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to transform healthcare for military personnel, veterans, and the broader public. Alcamena...